Overview

Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin

Status:
RECRUITING

Trial end date:
2029-10-31

Target enrollment:

Participant gender:

Summary

This prospective, randomized, controlled phase II study aims to evaluate the efficacy of combination therapy with Envafolimab and chemotherapy in first-line extensive stage SCLC, as well as the impact of Trilaciclib on the incidence of myelosuppression and anti-tumor effects in patients.

Phase:

PHASE2

Details

Lead Sponsor:

Shanghai Chest Hospital

Collaborator:

Jiangsu Simcere Pharmaceutical Co., Ltd.

Treatments:

Carboplatin
EC regimen
envafolimab
trilaciclib